Fibromyalgia syndrome in need of effective treatments.

Theoharis C Theoharides, Irene Tsilioni, Lauren Arbetman, Smaro Panagiotidou, Julia M Stewart, Rae M Gleason, Irwin J Russell

Journal: The Journal of pharmacology and experimental therapeutics 2016;355(2):255-63

PMID: 26306765

Free Full Text on PubMed Central View on PubMed

Abstract

Fibromyalgia syndrome (FMS) is a chronic, idiopathic condition of widespread musculoskeletal pain, affecting primarily women. It is clinically characterized by chronic, nonarticular pain and a heightened response to pressure along with sleep disturbances, fatigue, bowel and bladder abnormalities, and cognitive dysfunction. The diagnostic criteria have changed repeatedly, and there is neither a definitive pathogenesis nor reliable diagnostic or prognostic biomarkers. Clinical and laboratory studies have provided evidence of altered central pain pathways. Recent evidence suggests the involvement of neuroinflammation with stress peptides triggering the release of neurosenzitizing mediators. The management of FMS requires a multidimensional approach including patient education, behavioral therapy, exercise, and pain management. Here we review recent data on the pathogenesis and propose new directions for research and treatment.

Address: Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts (T.C.T., I.T., L.A., S.P., J.M.S.); Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.); Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.); Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (T.C.T.); National Fibromyalgia and Chronic Pain Association, Logan, Utah (R.M.G.); Fibromyalgia Research and Consulting, Arthritis and Osteoporosis Center of South Texas, San Antonio, Texas (I.J.R.) [email protected].; Department of Integrative Physiology and Pathobiology, Tufts University School of Medicine, Boston, Massachusetts (T.C.T., I.T., L.A., S.P., J.M.S.); Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.); Department of Psychiatry, Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts (T.C.T.); Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts (T.C.T.); National Fibromyalgia and Chronic Pain Association, Logan, Utah (R.M.G.); Fibromyalgia Research and Consulting, Arthritis and Osteoporosis Center of South Texas, San Antonio, Texas (I.J.R.).

DOI: 10.1124/jpet.115.227298

Link outs

Free resources

Full Text Sources:

Medical:

https://medlineplus.gov/fibromyalgia.html

Other Literature Sources:

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-3547

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0022...

MeSH Terms: Anticonvulsants, Antidepressive Agents, Cognitive Behavioral Therapy, Dietary Supplements, Fibromyalgia, Humans, Neuromuscular Agents, Patient Education as Topic, Syndrome